Ezetimibe is a cholesterol absorption inhibitor indicated for primary hyperlipidemia, alone or with a statin. We supply it to US manufacturers of tablets and fixed-dose combinations.
Data from PubChem (CID 150311) and FDA’s substance registry
CAS number
163222-33-1
Molecular formula
C24H21F2NO3
Molecular weight
409.4g/mol
FDA UNII
IUPAC name
(3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one
InChIKey
OLNTVTPDXPETLC-XPWALMASSA-N
- Appearance
- White to off-white crystalline powder.
- Solubility
- Practically insoluble in water. Freely soluble in methanol and acetone, and soluble in ethanol.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Practically insoluble in water, so most formulations need micronized material. State the particle size you developed with.
On the US market
- Reference product
- ZetiaNDA 021445
- Approved ANDAs
- 11 with a marketed product
- Approved forms and strengths
- Tablet 10 mg
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com